{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:46:42Z","timestamp":1774532802076,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1111\/igc.0b013e3181a1cc02","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:30:18Z","timestamp":1291383018000},"page":"367-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?"],"prefix":"10.1016","volume":"19","author":[{"given":"Angiolo","family":"Gadducci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Fuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Cosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Maggino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Perotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Testa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Galletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Zola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0005","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynecol Obstet."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0010","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","article-title":"Role of surgery in ovarian carcinoma","volume":"25","author":"Fader","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0015","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1200\/JCO.2007.11.1013","article-title":"Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature","volume":"25","author":"Trope\u00b4 C, Kaern J.","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oxfordjournals.annonc.a059355","article-title":"Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)","volume":"6","author":"Bolis","year":"1995","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1525-1438.1997.09742.x","article-title":"Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study","volume":"7","author":"Gadducci","year":"1997","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0030","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Semin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/gyno.1997.4890","article-title":"Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study","volume":"68","author":"Gadducci","year":"1998","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2005.03.003","article-title":"Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature","volume":"55","author":"Gadducci","year":"2005","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0045","first-page":"1","volume":"12","year":"1994","journal-title":"NIH Consens Statement."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0093-7754(03)00100-3","article-title":"The follow-up of ovarian cancer","volume":"30","author":"Vaidya","year":"2003","journal-title":"Semin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejogrb.2003.10.029","article-title":"Post-therapy surveillance and after-care in ovarian cancer","volume":"114","author":"von Georgi","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","article-title":"Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature","volume":"17","author":"Gadducci","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0065","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1525-1438.2007.00943.x","article-title":"Follow-up strategies in gynecological oncology: searching appropriateness","volume":"17","author":"Zola","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0075","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA 125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","article-title":"Relapsed ovarian cancer: challenges and management strategies for a chronic disease","volume":"7","author":"Armstrong","year":"2002","journal-title":"Oncologist."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum Reprod."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biopha.2003.11.003","article-title":"Serum tumor markers in the management of ovarian, endometrial and cervical cancer","volume":"58","author":"Gadducci","year":"2004","journal-title":"Biomed Pharmacother."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0095","first-page":"239","article-title":"The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries","volume":"178","author":"Kainz","year":"1994","journal-title":"J Am Coll Surg."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0020-7292(96)02721-X","article-title":"Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer","volume":"54","author":"Sugiyama","year":"1996","journal-title":"Int J Gynaecol Obstet."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0105","first-page":"269","article-title":"Pelvic relapses in ovarian cancer. Role of CA-125, transvaginal ultrasound and color Doppler","volume":"24","author":"Caserta","year":"2003","journal-title":"Eur J Gynaecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0110","first-page":"1551","article-title":"Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients","volume":"25","author":"Fehm","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0115","first-page":"746","article-title":"The value of FDG PET\/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma","volume":"77","author":"Grabiec","year":"2006","journal-title":"Ginekol Pol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0899-7071(98)00023-0","article-title":"Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history","volume":"22","author":"Ferrozzi","year":"1998","journal-title":"Clin Imaging."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s003300051000","article-title":"Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma","volume":"10","author":"Kubik-Huch","year":"2000","journal-title":"Eur Radiol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00261-007-9218-0","article-title":"PET-CT vs. CT alone in ovarian cancer recurrence","volume":"33","author":"Sebastian","year":"2008","journal-title":"Abdom Imaging."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0135","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0140","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminoncol.2005.06.023","article-title":"Gemcitabine and carboplatin in second-line ovarian cancer","volume":"32","author":"Ozols","year":"2005","journal-title":"Semin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0145","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ncponc0637","article-title":"Ovarian cancer: a focus on management of recurrent disease","volume":"3","author":"Herzog","year":"2006","journal-title":"Nat Clin Pract Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0150","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.03.012","article-title":"The management of recurrent ovarian cancer","volume":"34","author":"Bukowski","year":"2007","journal-title":"Semin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0155","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9378(98)70473-9","article-title":"Field cancerization: why late \u201crecurrent\u201d ovarian cancer is not recurrent","volume":"178","author":"Buller","year":"1998","journal-title":"Am J Obstet Gynecol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(07)70273-5","article-title":"Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations","volume":"8","author":"Goonewardene","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2214\/ajr.179.2.1790391","article-title":"Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer","volume":"179","author":"Cho","year":"2002","journal-title":"AJR Am J Roentgenol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0090-8258(03)00336-6","article-title":"Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined FDG-PET\/CT","volume":"90","author":"Bristow","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0175","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00261-003-0118-7","article-title":"FDG-PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation","volume":"29","author":"Pannu","year":"2004","journal-title":"Abdom Imaging."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0180","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00259-006-0260-x","article-title":"Role of [18F]FDG PET\/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings","volume":"34","author":"Chung","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0185","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/gyno.2001.6386","article-title":"2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer","volume":"83","author":"Zimny","year":"2001","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0190","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/gyno.2002.6611","article-title":"Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer","volume":"85","author":"Bristow","year":"2002","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1102\/1470-7330.2006.0005","article-title":"Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18 F-FDG-PET\/CT: an unusual finding","volume":"6","author":"Fanti","year":"2006","journal-title":"Cancer Imaging."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","article-title":"The impact of PET\/CT in the management of recurrent ovarian cancer","volume":"103","author":"Simcock","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0205","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0210","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0215","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer."},{"key":"10.1111\/IGC.0b013e3181a1cc02_bb0220","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-006-0306-0","article-title":"Integrated PET\/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer","volume":"34","author":"Mangili","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181a1cc02","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24027002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24027002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181a1cc02","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:23:14Z","timestamp":1753222994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24027002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1048891X24027002"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181a1cc02","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181a1cc02","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 IGCS and ESGO","name":"copyright","label":"Copyright"}]}}